Annuncio • Jun 30
Hualan Biological Engineering Inc. to Report First Half, 2026 Results on Aug 29, 2026 Hualan Biological Engineering Inc. announced that they will report first half, 2026 results on Aug 29, 2026 Annuncio • Jun 10
Hualan Biological Engineering Inc. Announces 2025 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 15 June 2026 Hualan Biological Engineering Inc. announced 2025 final profit distribution plan to be implemented (A shares) of CNY 5.00000000 per 10 shares(tax included). Record date: 12 June 2026, Ex-date: 15 June 2026, Payment date: 15 June 2026. Major Estimate Revision • Apr 03
Consensus EPS estimates fall by 14% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from CN¥5.36b to CN¥5.13b. EPS estimate also fell from CN¥0.778 per share to CN¥0.666 per share. Net income forecast to grow 30% next year vs 38% growth forecast for Biotechs industry in China. Consensus price target down from CN¥18.88 to CN¥17.55. Share price was steady at CN¥14.61 over the past week. Price Target Changed • Mar 31
Price target decreased by 7.1% to CN¥17.55 Down from CN¥18.88, the current price target is an average from 4 analysts. New target price is 20% above last closing price of CN¥14.65. Stock is down 9.5% over the past year. The company is forecast to post earnings per share of CN¥0.67 for next year compared to CN¥0.52 last year. Annuncio • Mar 31
Hualan Biological Engineering Inc. to Report Q1, 2026 Results on Apr 27, 2026 Hualan Biological Engineering Inc. announced that they will report Q1, 2026 results on Apr 27, 2026 Reported Earnings • Mar 29
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.52 (down from CN¥0.60 in FY 2024). Revenue: CN¥4.60b (up 4.9% from FY 2024). Net income: CN¥940.4m (down 14% from FY 2024). Profit margin: 21% (down from 25% in FY 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) also missed analyst estimates by 22%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings. Annuncio • Mar 28
Hualan Biological Engineering Inc., Annual General Meeting, Apr 20, 2026 Hualan Biological Engineering Inc., Annual General Meeting, Apr 20, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinxiang, Henan China Annuncio • Dec 31
Hualan Biological Engineering Inc. to Report Fiscal Year 2025 Results on Mar 28, 2026 Hualan Biological Engineering Inc. announced that they will report fiscal year 2025 results on Mar 28, 2026 Buy Or Sell Opportunity • Nov 17
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 2.4% to CN¥16.42. The fair value is estimated to be CN¥20.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 41% in 2 years. Earnings are forecast to grow by 74% in the next 2 years. Reported Earnings • Oct 31
Third quarter 2025 earnings: EPS and revenues miss analyst expectations Third quarter 2025 results: EPS: CN¥0.15 (down from CN¥0.27 in 3Q 2024). Revenue: CN¥1.58b (down 14% from 3Q 2024). Net income: CN¥268.6m (down 44% from 3Q 2024). Profit margin: 17% (down from 26% in 3Q 2024). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 25%. Earnings per share (EPS) also missed analyst estimates by 52%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 4% per year. Buy Or Sell Opportunity • Oct 27
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 4.0% to CN¥16.14. The fair value is estimated to be CN¥20.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 39% in the next 2 years. Annuncio • Sep 30
Hualan Biological Engineering Inc. to Report Q3, 2025 Results on Oct 30, 2025 Hualan Biological Engineering Inc. announced that they will report Q3, 2025 results on Oct 30, 2025 Annuncio • Sep 24
Hualan Biological Engineering Inc. Approves Interim Dividend for 2025 Hualan Biological Engineering Inc. held its 2nd Extraordinary General Meeting of 2025 on 22 September 2025, approved interim Cash dividend/10 shares (tax included): CNY5.00000000 for 2025. Buy Or Sell Opportunity • Sep 04
Now 20% undervalued Over the last 90 days, the stock has risen 2.1% to CN¥16.50. The fair value is estimated to be CN¥20.65, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 31% in 2 years. Earnings are forecast to grow by 40% in the next 2 years. Annuncio • Aug 29
Hualan Biological Engineering Inc. Proposes Interim Cash Dividend for 2025 Hualan Biological Engineering Inc. at its EGM to be held on September 22, 2025, proposed the detailed profit distribution plan are as follows: Cash dividend/10 shares (tax included): CNY5.00000000. Reported Earnings • Aug 28
Second quarter 2025 earnings: EPS in line with expectations, revenues disappoint Second quarter 2025 results: EPS: CN¥0.11 (up from CN¥0.098 in 2Q 2024). Revenue: CN¥930.6m (up 7.5% from 2Q 2024). Net income: CN¥202.7m (up 14% from 2Q 2024). Profit margin: 22% (up from 21% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year. Buy Or Sell Opportunity • Jul 23
Now 20% undervalued The stock has been flat over the last 90 days, currently trading at CN¥16.36. The fair value is estimated to be CN¥20.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 31% in 2 years. Earnings are forecast to grow by 41% in the next 2 years. Annuncio • Jul 02
Hualan Biological Engineering Inc. to Report First Half, 2025 Results on Aug 29, 2025 Hualan Biological Engineering Inc. announced that they will report first half, 2025 results on Aug 29, 2025 Buy Or Sell Opportunity • Jun 16
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 2.9% to CN¥15.89. The fair value is estimated to be CN¥20.10, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 31% in 2 years. Earnings are forecast to grow by 41% in the next 2 years. Declared Dividend • Jun 13
Dividend reduced to CN¥0.20 Dividend of CN¥0.20 is 33% lower than last year. Ex-date: 17th June 2025 Payment date: 17th June 2025 Dividend yield will be 1.2%, which is lower than the industry average of 1.6%. Sustainability & Growth Dividend is well covered by both earnings (32% earnings payout ratio) and cash flows (45% cash payout ratio). The dividend has increased over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 55% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Buy Or Sell Opportunity • May 23
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 3.1% to CN¥15.87. The fair value is estimated to be CN¥20.10, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 33% in 2 years. Earnings are forecast to grow by 41% in the next 2 years. Reported Earnings • Apr 29
First quarter 2025 earnings: EPS and revenues exceed analyst expectations First quarter 2025 results: EPS: CN¥0.17 (up from CN¥0.14 in 1Q 2024). Revenue: CN¥867.6m (up 10% from 1Q 2024). Net income: CN¥313.1m (up 20% from 1Q 2024). Profit margin: 36% (up from 33% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates by 22%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 1% per year. Major Estimate Revision • Apr 04
Consensus revenue estimates fall by 16% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥6.10b to CN¥5.11b. EPS estimate fell from CN¥0.935 to CN¥0.721 per share. Net income forecast to grow 21% next year vs 37% growth forecast for Biotechs industry in China. Consensus price target down from CN¥20.70 to CN¥19.77. Share price was steady at CN¥16.25 over the past week. Annuncio • Apr 01
Hualan Biological Engineering Inc. Proposes Final Cash Dividend for the Year 2024 Hualan Biological Engineering Inc. announced on 31 March 2025 the profit distribution proposal for the year 2024 as final cash dividend/10 shares (tax included) of CNY 2.00000000. Annuncio • Mar 31
Hualan Biological Engineering Inc. to Report Q1, 2025 Results on Apr 28, 2025 Hualan Biological Engineering Inc. announced that they will report Q1, 2025 results on Apr 28, 2025 Reported Earnings • Mar 30
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.60 (down from CN¥0.81 in FY 2023). Revenue: CN¥4.38b (down 18% from FY 2023). Net income: CN¥1.09b (down 27% from FY 2023). Profit margin: 25% (down from 28% in FY 2023). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 19%. Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Annuncio • Mar 29
Hualan Biological Engineering Inc., Annual General Meeting, Apr 25, 2025 Hualan Biological Engineering Inc., Annual General Meeting, Apr 25, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xinxiang, Henan China Annuncio • Dec 31
Hualan Biological Engineering Inc. to Report Fiscal Year 2024 Results on Mar 29, 2025 Hualan Biological Engineering Inc. announced that they will report fiscal year 2024 results on Mar 29, 2025 Reported Earnings • Oct 30
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: EPS: CN¥0.27 (down from CN¥0.30 in 3Q 2023). Revenue: CN¥1.84b (down 21% from 3Q 2023). Net income: CN¥483.5m (down 11% from 3Q 2023). Profit margin: 26% (up from 23% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 19%. Earnings per share (EPS) also missed analyst estimates by 19%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings. Annuncio • Sep 30
Hualan Biological Engineering Inc. to Report Q3, 2024 Results on Oct 31, 2024 Hualan Biological Engineering Inc. announced that they will report Q3, 2024 results on Oct 31, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥16.41, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 21x in the Biotechs industry in China. Total loss to shareholders of 39% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥27.87 per share. Price Target Changed • Sep 02
Price target decreased by 7.4% to CN¥22.68 Down from CN¥24.48, the current price target is an average from 7 analysts. New target price is 52% above last closing price of CN¥14.91. Stock is down 30% over the past year. The company is forecast to post earnings per share of CN¥0.89 for next year compared to CN¥0.81 last year. Reported Earnings • Aug 30
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2024 results: EPS: CN¥0.098 (up from CN¥0.096 in 2Q 2023). Revenue: CN¥865.4m (up 23% from 2Q 2023). Net income: CN¥178.4m (up 2.0% from 2Q 2023). Profit margin: 21% (down from 25% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates by 29%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings. Annuncio • Jun 29
Hualan Biological Engineering Inc. to Report First Half, 2024 Results on Aug 30, 2024 Hualan Biological Engineering Inc. announced that they will report first half, 2024 results on Aug 30, 2024 Declared Dividend • Jun 08
Dividend of CN¥0.30 announced Dividend of CN¥0.30 is the same as last year. Ex-date: 14th June 2024 Payment date: 14th June 2024 Dividend yield will be 1.7%, which is about the same as the industry average. Sustainability & Growth Dividend is covered by earnings (39% earnings payout ratio) but not covered by cash flows (159% cash payout ratio). The dividend has increased by an average of 25% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 62% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Annuncio • Jun 08
Hualan Biological Engineering Inc. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2023, Payable on 14 June 2024 Hualan Biological Engineering Inc. announced final profit distribution plan to be implemented on A shares as cash dividend per ten shares (tax included) of CNY 3.00000000 for the year 2023, payable on 14 June 2024. Record date: 13 June 2024. Ex-date: 14 June 2024. Reported Earnings • Apr 26
First quarter 2024 earnings: EPS and revenues exceed analyst expectations First quarter 2024 results: EPS: CN¥0.14 (down from CN¥0.19 in 1Q 2023). Revenue: CN¥787.3m (down 11% from 1Q 2023). Net income: CN¥261.8m (down 26% from 1Q 2023). Profit margin: 33% (down from 40% in 1Q 2023). Revenue exceeded analyst estimates by 3.7%. Earnings per share (EPS) also surpassed analyst estimates by 10%. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Reported Earnings • Apr 01
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2023 results: EPS: CN¥0.81 (up from CN¥0.59 in FY 2022). Revenue: CN¥5.34b (up 18% from FY 2022). Net income: CN¥1.48b (up 38% from FY 2022). Profit margin: 28% (up from 24% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) exceeded analyst estimates by 2.8%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings. Annuncio • Mar 30
Hualan Biological Engineering Inc. to Report Q1, 2024 Results on Apr 26, 2024 Hualan Biological Engineering Inc. announced that they will report Q1, 2024 results on Apr 26, 2024 Annuncio • Dec 30
Hualan Biological Engineering Inc. to Report Fiscal Year 2023 Results on Mar 30, 2024 Hualan Biological Engineering Inc. announced that they will report fiscal year 2023 results on Mar 30, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2023 results: EPS: CN¥0.30 (up from CN¥0.17 in 3Q 2022). Revenue: CN¥2.33b (up 86% from 3Q 2022). Net income: CN¥540.6m (up 70% from 3Q 2022). Profit margin: 23% (down from 25% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 1.8%. Earnings per share (EPS) missed analyst estimates by 38%. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 20% per year, which means it is performing significantly worse than earnings. Reported Earnings • Aug 24
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2023 results: EPS: CN¥0.096 (down from CN¥0.19 in 2Q 2022). Revenue: CN¥704.6m (down 59% from 2Q 2022). Net income: CN¥175.0m (down 50% from 2Q 2022). Profit margin: 25% (up from 20% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 10%. Earnings per share (EPS) exceeded analyst estimates by 11%. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings. Annuncio • Jun 08
Hualan Biological Engineering Inc. Announces Final Dividend on Share A for 2022, Payable on June 14, 2023 Hualan Biological Engineering Inc. announced final Cash dividend/10 shares (tax included): CNY 3.00000000 on share A for 2022. Record date: 13 June 2023, Ex-date: 14 June 2023, Payment date: 14 June 2023. Reported Earnings • Mar 30
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥0.59 (down from CN¥0.71 in FY 2021). Revenue: CN¥4.52b (up 1.8% from FY 2021). Net income: CN¥1.08b (down 17% from FY 2021). Profit margin: 24% (down from 29% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 9.2%. Earnings per share (EPS) also missed analyst estimates by 25%. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings. Price Target Changed • Jan 17
Price target increased to CN¥26.17 Up from CN¥24.17, the current price target is an average from 4 analysts. New target price is 13% above last closing price of CN¥23.23. Stock is down 22% over the past year. The company is forecast to post earnings per share of CN¥0.80 for next year compared to CN¥0.71 last year. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Yunlong Wang was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 31
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2022 results: EPS: CN¥0.17 (down from CN¥0.33 in 3Q 2021). Revenue: CN¥1.25b (down 40% from 3Q 2021). Net income: CN¥317.6m (down 47% from 3Q 2021). Profit margin: 25% (down from 29% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) missed analyst estimates by 40%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥20.15, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 28x in the Biotechs industry in China. Total loss to shareholders of 27% over the past three years. Reported Earnings • Aug 24
Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.11 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.19 (up from CN¥0.11 in 2Q 2021). Revenue: CN¥1.71b (up 157% from 2Q 2021). Net income: CN¥349.1m (up 71% from 2Q 2021). Profit margin: 20% (down from 31% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to stay flat compared to a 34% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥22.86, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 30x in the Biotechs industry in China. Total returns to shareholders of 4.3% over the past three years. Annuncio • Jun 09
Hualan Biological Engineering Inc. Announces Final Cash Dividend on A Shares for 2021, Payable on 16 June 2022 Hualan Biological Engineering Inc. announced final cash dividend of CNY 2.00000000 per 10 shares on A shares for 2021. Record date is 15 June 2022, Ex-date is 16 June 2022 and Payment date is 16 June 2022. Price Target Changed • Jun 01
Price target decreased to CN¥27.73 Down from CN¥33.57, the current price target is an average from 9 analysts. New target price is 50% above last closing price of CN¥18.50. Stock is down 52% over the past year. The company is forecast to post earnings per share of CN¥0.82 for next year compared to CN¥0.71 last year. Board Change • May 24
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Yunlong Wang was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • May 24
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥19.23, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 30x in the Biotechs industry in China. Total loss to shareholders of 9.4% over the past three years. Major Estimate Revision • Apr 30
Consensus revenue estimates increase by 11% The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from CN¥5.39b to CN¥5.96b. EPS estimate increased from CN¥0.94 to CN¥1.01 per share. Net income forecast to grow 43% next year vs 33% growth forecast for Biotechs industry in China. Consensus price target down from CN¥33.57 to CN¥32.08. Share price was steady at CN¥16.69 over the past week. Price Target Changed • Apr 27
Price target decreased to CN¥33.57 Down from CN¥36.80, the current price target is an average from 9 analysts. New target price is 111% above last closing price of CN¥15.91. Stock is down 64% over the past year. The company is forecast to post earnings per share of CN¥0.94 for next year compared to CN¥0.71 last year. Price Target Changed • Apr 07
Price target decreased to CN¥33.57 Down from CN¥36.80, the current price target is an average from 11 analysts. New target price is 71% above last closing price of CN¥19.65. Stock is down 54% over the past year. The company is forecast to post earnings per share of CN¥0.95 for next year compared to CN¥0.71 last year. Annuncio • Apr 02
Hualan Biological Engineering Inc., Annual General Meeting, Apr 28, 2022 Hualan Biological Engineering Inc., Annual General Meeting, Apr 28, 2022, at 14:30 China Standard Time. Agenda: To consider 2021 work report of the board of directors; to consider 2021 work report of the supervisory committee; to consider 2021 annual report and its summary; to consider 2021 annual accounts; to consider 2021 profit distribution plan; to consider investment and wealth management with proprietary funds; to consider reappointment of 2022 audit firm; to consider amendments to the articles of associations; to consider amendments to the rules of procedure governing shareholders' general meetings; to consider amendments to the rules of procedure governing the board of directors; to consider election of non-independent directors, cumulative voting system applicable; and to consider others. Reported Earnings • Apr 01
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: EPS: CN¥0.71 (down from CN¥0.89 in FY 2020). Revenue: CN¥4.44b (down 12% from FY 2020). Net income: CN¥1.30b (down 20% from FY 2020). Profit margin: 29% (down from 32% in FY 2020). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 23%. Earnings per share (EPS) also missed analyst estimates by 30%. Over the next year, revenue is forecast to grow 9.4%, compared to a 51% growth forecast for the pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Annuncio • Mar 31
Hualan Biological Engineering Inc. Proposes Final Dividend for the Year 2021 Hualan Biological Engineering Inc. announced on 30 March 2022 the profit distribution proposal for 2021 as follows: Cash dividend/10 shares (tax included): CNY 2.00000000. Major Estimate Revision • Mar 31
Consensus revenue estimates fall by 32% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from CN¥7.00b to CN¥4.75b. EPS estimate fell from CN¥1.24 to CN¥0.79 per share. Net income forecast to shrink 9.3% next year vs 41% growth forecast for Biotechs industry in China . Consensus price target broadly unchanged at CN¥36.14. Share price fell 12% to CN¥20.31 over the past week. Price Target Changed • Mar 17
Price target decreased to CN¥36.80 Down from CN¥41.22, the current price target is an average from 10 analysts. New target price is 63% above last closing price of CN¥22.61. Stock is down 43% over the past year. The company is forecast to post earnings per share of CN¥1.02 for next year compared to CN¥0.89 last year. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.33 (vs CN¥0.25 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥2.07b (up 23% from 3Q 2020). Net income: CN¥599.5m (up 33% from 3Q 2020). Profit margin: 29% (up from 27% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 16% per year. Price Target Changed • Sep 22
Price target decreased to CN¥41.06 Down from CN¥45.55, the current price target is an average from 13 analysts. New target price is 49% above last closing price of CN¥27.56. Stock is down 48% over the past year. Valuation Update With 7 Day Price Move • Sep 02
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥29.89, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 35x in the Biotechs industry in China. Total returns to shareholders of 70% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥20.70 per share. Price Target Changed • Aug 31
Price target decreased to CN¥46.66 Down from CN¥50.28, the current price target is an average from 11 analysts. New target price is 59% above last closing price of CN¥29.43. Stock is down 47% over the past year. Reported Earnings • Aug 30
Second quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.14 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥665.2m (down 6.2% from 2Q 2020). Net income: CN¥204.5m (down 23% from 2Q 2020). Profit margin: 31% (down from 37% in 2Q 2020). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 17% per year and the company’s share price has also increased by 17% per year. Reported Earnings • May 02
First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.14 in 1Q 2020) The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: CN¥623.4m (down 8.0% from 1Q 2020). Net income: CN¥252.8m (up 2.2% from 1Q 2020). Profit margin: 41% (up from 37% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 40% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Mar 31
Full year 2020 earnings released: EPS CN¥0.89 (vs CN¥0.71 in FY 2019) The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥5.02b (up 36% from FY 2019). Net income: CN¥1.61b (up 26% from FY 2019). Profit margin: 32% (down from 35% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Mar 11
Full year 2020 earnings released: EPS CN¥0.88 (vs CN¥0.70 in FY 2019) The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥5.02b (up 36% from FY 2019). Net income: CN¥1.60b (up 25% from FY 2019). Profit margin: 32% (down from 35% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth. Analyst Estimate Surprise Post Earnings • Mar 11
Revenue beats expectations, earnings disappoint Revenue exceeded analyst estimates by 6.3%. Earnings per share (EPS) missed analyst estimates by 2.5%. Over the next year, revenue is forecast to grow 9.6%, compared to a 61% growth forecast for the Biotechs industry in China. Is New 90 Day High Low • Mar 08
New 90-day low: CN¥39.55 The company is down 10.0% from its price of CN¥43.73 on 08 December 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥47.97 per share. Annuncio • Feb 25
Hualan Biological Engineering Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021 Hualan Biological Engineering Inc. announced that they will report fiscal year 2020 results on Mar 30, 2021 Valuation Update With 7 Day Price Move • Feb 10
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥53.98, the stock is trading at a trailing P/E ratio of 76.7x, up from the previous P/E ratio of 66.4x. This compares to an average P/E of 67x in the Biotechs industry in China. Total returns to shareholders over the past three years are 323%. Is New 90 Day High Low • Feb 10
New 90-day high: CN¥53.98 The company is up 22% from its price of CN¥44.33 on 12 November 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥44.97 per share. Valuation Update With 7 Day Price Move • Jan 08
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥50.39, the stock is trading at a trailing P/E ratio of 71.6x, up from the previous P/E ratio of 60x. This compares to an average P/E of 65x in the Biotechs industry in China. Total returns to shareholders over the past three years are 261%. Is New 90 Day High Low • Nov 23
New 90-day low: CN¥42.50 The company is down 24% from its price of CN¥55.97 on 25 August 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥23.06 per share. Is New 90 Day High Low • Nov 02
New 90-day low: CN¥46.08 The company is down 33% from its price of CN¥68.48 on 04 August 2020. The Chinese market is down 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 21% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥25.56 per share. Reported Earnings • Nov 01
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥1.28b, down 4.4% from the prior year. Total revenue was CN¥4.13b over the last 12 months, up 8.3% from the prior year. Analyst Estimate Surprise Post Earnings • Nov 01
Third-quarter earnings released: Revenue beats expectations, earnings disappoint Third-quarter revenue exceeded analyst estimates by 14% at CN¥1.69b. Earnings per share (EPS) missed analyst estimates by 19% at CN¥0.25. Revenue is forecast to grow 26% over the next year, compared to a 41% growth forecast for the Biotechs industry in China. Valuation Update With 7 Day Price Move • Oct 23
Market pulls back on stock over the past week After last week's 15% share price decline to CN¥51.27, the stock is trading at a trailing P/E ratio of 72.6x, down from the previous P/E ratio of 85.5x. This compares to an average P/E of 78x in the Biotechs industry in China. Total returns to shareholders over the past three years are 251%. 
